Challenges in CNS Drug Discovery:
- The development of drugs for central nervous system disorders faces challenges such as poor translation from in vitro to in vivo models, leading to unreliable outcomes in later stages.
- The optimization of blood-brain barrier (BBB) permeability has been found to be both expensive and inefficient.
- The absence of quantitative biomarkers for evaluating the activity and progression of CNS drugs is a significant issue.
- The decision-making process on candidate compounds is delayed due to insufficient in vivo data.
ZEFIT Innovative Solutions:
- Zebrafish-based discovery is a cost-effective and scalable vertebrate model that provides real-time, whole-organism insights into the effects of CNS drugs.
- Quantitative EEG-based biomarkers are objective indicators from biosignals that help measure brain activity and how the body responds to drugs.
- In-Vivo Big Data Integration is a tool that utilizes a growing dataset of pharmacological effects to predict compound behavior early in development.
CNS-Focused Drug Discovery Platform:
- ZEFIT modular, efficient CNS drug development platform utilizes high-throughput in vivo screening to quickly identify compounds with therapeutic potential for CNS disorders.
- The therapeutic index optimization platform optimizes dosage ranges and treatment windows by balancing safety and efficacy.
- The stability optimization platform enhances compound durability and bioavailability by assessing chemical and biological stability early.
- The BBB delivery optimization platform develops and validates drug delivery methods that improve BBB permeability, utilizing in vivo metrics and real-time data to expedite results.
If you are looking for a pharmaceutical innovation, you can find them at ZEFIT.
Click here if you are interested in ZEFIT services.
View more: Advancing CNS Drug Discovery with Smart In-Vivo Science